A biomarker and therapeutical target in immune thrombocytopenia: TNF receptor-associated factor 6
Veysi Asoglu1, Elif G Umit1, Muzaffer Demir1
1Department of Hematology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Background:
Immune thrombocytopenia (ITP) is an acquired disease characterized by various pathogenetic mechanisms. We aimed to evaluate the value of TRAF6 as a biomarker of pathogenesis in ITP.
Methods:
85 newly diagnosed ITP patients and 85 controls were included.
Results:
In the patient group, mean TRAF6 level was 2348 pg/ml and in the control group, TRAF6 level was 25.57 pg/ml. In corticosteroid-responding patients, TRAF6 levels were lower than nonresponding patients.
Discussion:
TRAF6 levels were observed to be higher than healthy controls, which suggest a solid relation with ITP pathogenesis. The observation that in patients who present with high TRAF6 levels, there was a significant corticosteroid refractoriness and responsiveness.
More Related Videos
16:07Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
09:51Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Internal Receptors
What is the Immune System?
Humoral Immune Responses
Therapeutic Index
Transcription Factors
